2022 IPO

Prime Medicine Stock

Prime Medicine operates as a biotechnology company.

Sign up today and learn more about Prime Medicine Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Prime Medicine Stock

Prime Medicine is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly "search and replace" to restore normal genetic function and address the fundamental causes of disease.


Funding History

October 2019$115M
July 2021$200M


Board Member

Stephen Knight

Board Member

Robert Nelsen

Board Member

John Evans

Chief Scientific Officer

Jeremy Duffield

President & Chief Executive Office

Keith M. Gottesdiener

Board Member

Keith M. Gottesdiener

Board Member

David Schenkein


Andrew Anzalone

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: